Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) was upgraded by equities researchers at TheStreet from a “c+” rating to a “b-” rating in a research note issued to investors on Tuesday, TheStreetRatingsTable reports.
Other equities research analysts have also issued research reports about the stock. HC Wainwright began coverage on shares of Horizon Therapeutics Public in a report on Tuesday, November 1st. They set a “neutral” rating and a $74.00 target price for the company. StockNews.com raised shares of Horizon Therapeutics Public from a “hold” rating to a “buy” rating in a research report on Thursday, November 3rd. SVB Leerink boosted their price target on shares of Horizon Therapeutics Public from $80.00 to $88.00 and gave the company an “outperform” rating in a research report on Thursday, November 3rd. BMO Capital Markets lowered their price target on shares of Horizon Therapeutics Public from $145.00 to $117.00 and set an “outperform” rating on the stock in a research report on Thursday, August 4th. Finally, Morgan Stanley decreased their target price on shares of Horizon Therapeutics Public from $135.00 to $90.00 and set an “overweight” rating on the stock in a research report on Thursday, August 4th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $105.00.
Horizon Therapeutics Public Price Performance
Horizon Therapeutics Public stock opened at $77.53 on Tuesday. Horizon Therapeutics Public has a 52-week low of $57.84 and a 52-week high of $117.49. The firm has a market capitalization of $17.57 billion, a price-to-earnings ratio of 31.77, a PEG ratio of 1.54 and a beta of 1.09. The company has a fifty day simple moving average of $67.51 and a 200-day simple moving average of $74.32. The company has a quick ratio of 3.74, a current ratio of 3.96 and a debt-to-equity ratio of 0.51.
Institutional Trading of Horizon Therapeutics Public
Horizon Therapeutics Public Company Profile
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.
- Get a free copy of the StockNews.com research report on Horizon Therapeutics Public (HZNP)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.